With a median survival of 6 months and a five-year survival rate of less than 5%, pancreatic cancer is the most lethal of all cancer types. This dismal picture of pancreatic cancer is mainly due to the lack of early diagnosis and effective treatment for patients with advanced disease. To increase the survival rate of pancreatic cancer patients, improved tumor markers for diagnosis and new molecular targets for drug development are desperately needed. A lot of effort has been made in searching for genes causative to or associated with the progression of malignant behavior in pancreatic cancer. As a result, alterations in a number of cancer-related genes have been identified in pancreatic tumors. The identification and characterization of these cancer-related genes have significantly increased our understanding of pancreatic cancer tumorigenesis, progression, and metastasis. Unfortunately, the treatment of pancreatic cancer has yet to benefit from these findings as therapy has not advanced much in the past 20 years.
Over the past decade, tremendous advances have been made in the field of cancer drug discovery, particularly in the area of molecular and genetic models and technologies. Many of those advanced models and technologies have been applied to the drug discovery processes for pancreatic cancer. In this book, a team of experts describe the latest development in the application of these models and technologies in pancreatic cancer. The authors include basic scientists as well as clinicians, all who work on the front-line of the war against this disease and have first-hand experience on these cutting-edge tools and techniques. It is our hope that the knowledge presented in this book will provide a strong background for those who want to make an impact in the treatment of patients with this dreadful disease.
Contents
Over the past decade, tremendous advances have been made in the field of cancer drug discovery, particularly in the area of molecular and genetic models and technologies. Many of those advanced models and technologies have been applied to the drug discovery processes for pancreatic cancer. In this book, a team of experts describe the latest development in the application of these models and technologies in pancreatic cancer. The authors include basic scientists as well as clinicians, all who work on the front-line of the war against this disease and have first-hand experience on these cutting-edge tools and techniques. It is our hope that the knowledge presented in this book will provide a strong background for those who want to make an impact in the treatment of patients with this dreadful disease.
- 1 Drug Evaluations in Pancreatic Cancer Culture Systems
- 2 Mouse Xenograft Models for Drug Discovery in Pancreatic Cancer
- 3 Fluorescent Metastatic Mouse Models of Pancreatic Cancer for Drug Discovery
- 4 A New Preclinical Paradigm for Pancreas Cancer
- 5 Zebrafish as a Biological System for Identifying and Validating Therapeutic Targets and Compounds
- 6 Gene Expression Arrays in Pancreatic Cancer Drug Discovery Research
- 7 Using Array Comparative Genomic Hybridization of Pancreatic Cancer Samples to Map Interesting Regions for Target Gene Identification
- 8 The Application of High-Throughput RNAi in Pancreatic Cancer Target Discovery and Drug Development
- 9 MicroRNA Profiling and Its Application in Drug Discovery in Pancreatic Cancer
- 10 Methylation Detection and Epigenomics in Pancreatic Cancer
- 11 Tissue Microarray Applications in Drug Discovery for Pancreatic Cancer
- 12 Proteomic Analysis of Blood and Pancreatic Juice
- 13 Applications of Antibody-Lectin Sandwich Arrays (ALSA) to Pancreatic Cancer Diagnostics and Drug Discovery
- 14 The Development of Pharmacodynamic Endpoint Models for Evaluation of Therapeutics in Pancreatic Cancer
- Index
Product Details
- Hardcover: 352 pages
- Publisher: Springer; 1st edition (March 18, 2010)
- Language: English
- ISBN-10: 1441911596
- ISBN-13: 978-1441911599
- Product Dimensions: 9.2 x 6.1 x 0.9 inches